Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Mr. Adam H. SchechterPresident, CEO & Chairman | -5,90k | 1,50M | Automatic Disposition | 254,50 | 107,23k | -5,22% |
| 2026-03-26 | Mr. Adam H. SchechterPresident, CEO & Chairman | -26,11k | 7,01M | Sale to Issuer | 268,38 | 113,14k | -18,75% |
| 2026-03-26 | Ms. Anita Z. GrahamExec. VP & Chief HR Officer | -2,88k | 772,67k | Sale to Issuer | 268,38 | 5,19k | -35,70% |
| 2026-03-26 | Mr. Mark S. SchroederInsider | -6,07k | 1,63M | Sale to Issuer | 268,38 | 12,68k | -32,37% |
| 2026-03-26 | Dr. Brian J. CaveneyEVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | -4,91k | 1,32M | Sale to Issuer | 268,38 | 36,49k | -11,85% |
| 2026-03-27 | Mr. Peter J. WilkinsonSenior VP & CAO | -1,63k | 436,09k | Automatic Disposition | 267,05 | 1,85k | -46,86% |
| 2026-03-26 | Mr. Peter J. WilkinsonSenior VP & CAO | -755,00 | 202,63k | Sale to Issuer | 268,38 | 1,85k | -28,96% |
| 2026-03-26 | Mr. Bryan T. VaughnEVP & President of Diagnostics | -451,00 | 121,04k | Sale to Issuer | 268,38 | 6,75k | -6,27% |
| 2026-03-26 | Ms. Sandra D. van der VaartInsider | -2,72k | 730,53k | Sale to Issuer | 268,38 | 6,24k | -30,38% |
| 2026-03-26 | Ms. Amy B. SummyEVP, CMO & Consumer Health Lead | -1,84k | 492,75k | Sale to Issuer | 268,38 | 7,88k | -18,90% |
| 2026-03-26 | Mr. Akinbolade OyegunwaExec. VP and Chief Information & Technology Officer | -382,00 | 102,52k | Sale to Issuer | 268,38 | 5,06k | -7,01% |
| 2026-03-27 | Mr. Jonathan C. MeltzerEVP & Chief Operations Officer | -839,00 | 224,05k | Automatic Disposition | 267,05 | 3,62k | -18,82% |
| 2026-03-26 | Mr. Jonathan C. MeltzerEVP & Chief Operations Officer | -711,00 | 190,82k | Sale to Issuer | 268,38 | 3,62k | -16,42% |
| 2026-03-26 | Ms. Kathryn Wright KyleExec. VP, Chief Legal Officer and Corporate Secretary | -451,00 | 121,04k | Sale to Issuer | 268,38 | 4,58k | -8,97% |
| 2026-03-26 | Ms. Megan D. BaileyExec. VP and President of Central Laboratory Services & International Labcorp | -481,00 | 129,09k | Sale to Issuer | 268,38 | 4,85k | -9,02% |
| 2026-03-03 | Mr. Adam H. SchechterPresident, CEO & Chairman | -8,71k | 2,44M | Verkauf | 279,96 | 80,77k | -9,73% |
| 2026-02-27 | Ms. Sandra D. van der VaartInsider | -547,54 | 156,00k | Verkauf | 284,91 | 2,58k | -17,51% |
| 2026-02-24 | Dr. Brian J. CaveneyEVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | -1,50k | 429,46k | Verkauf | 286,31 | 30,11k | -4,75% |
| 2026-02-19 | Mr. Peter J. WilkinsonSenior VP & CAO | -666,00 | 185,11k | Automatic Disposition | 277,94 | 1,85k | -26,45% |
| 2026-02-11 | Ms. Amy B. SummyEVP, CMO & Consumer Health Lead | 147,00 | 0,00 | Derivative Exercise and Retained Stock | - | 5,72k | 2,64% |
| 2026-02-11 | Ms. Amy B. SummyEVP, CMO & Consumer Health Lead | -83,00 | 24,06k | Derivative Exercise and Sale | 289,89 | 5,72k | - |
| 2026-02-11 | Mr. Peter J. WilkinsonSenior VP & CAO | 490,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,52k | 24,16% |
| 2026-02-11 | Mr. Peter J. WilkinsonSenior VP & CAO | -206,00 | 59,72k | Derivative Exercise and Sale | 289,89 | 2,52k | - |
| 2026-02-11 | Ms. Julia A. WangCFO & Exec. VP | 615,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,82k | 51,16% |
| 2026-02-11 | Ms. Julia A. WangCFO & Exec. VP | -245,00 | 71,02k | Derivative Exercise and Sale | 289,89 | 1,82k | - |
| 2026-02-11 | Ms. Sandra D. van der VaartInsider | 277,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,13k | 9,72% |
| 2026-02-11 | Ms. Sandra D. van der VaartInsider | -99,00 | 28,70k | Derivative Exercise and Sale | 289,89 | 3,13k | - |
| 2026-02-11 | Mr. Bryan T. VaughnEVP & President of Diagnostics | 230,00 | 0,00 | Derivative Exercise and Retained Stock | - | 5,61k | 4,27% |
| 2026-02-11 | Mr. Bryan T. VaughnEVP & President of Diagnostics | -93,00 | 26,96k | Derivative Exercise and Sale | 289,89 | 5,61k | - |
| 2026-02-11 | Mr. Mark S. SchroederInsider | 547,00 | 0,00 | Derivative Exercise and Retained Stock | - | 6,47k | 9,23% |
| 2026-02-11 | Mr. Mark S. SchroederInsider | -259,00 | 75,08k | Derivative Exercise and Sale | 289,89 | 6,47k | - |
| 2026-02-11 | Mr. Adam H. SchechterPresident, CEO & Chairman | 2,14k | 0,00 | Derivative Exercise and Retained Stock | - | 89,48k | 2,44% |
| 2026-02-11 | Mr. Adam H. SchechterPresident, CEO & Chairman | -1,52k | 440,92k | Derivative Exercise and Sale | 289,89 | 89,48k | - |
| 2026-02-11 | Mr. Adam H. SchechterPresident, CEO & Chairman | -5,27k | 1,50M | Automatic Disposition | 284,38 | 89,48k | -5,57% |
| 2026-02-11 | Mr. Akinbolade OyegunwaExec. VP and Chief Information & Technology Officer | 162,00 | 0,00 | Derivative Exercise and Retained Stock | - | 4,11k | 4,11% |
| 2026-02-11 | Mr. Akinbolade OyegunwaExec. VP and Chief Information & Technology Officer | -68,00 | 19,71k | Derivative Exercise and Sale | 289,89 | 4,11k | - |
| 2026-02-11 | Ms. Kathryn Wright KyleExec. VP, Chief Legal Officer and Corporate Secretary | 154,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,44k | 4,68% |
| 2026-02-11 | Ms. Kathryn Wright KyleExec. VP, Chief Legal Officer and Corporate Secretary | -62,00 | 17,97k | Derivative Exercise and Sale | 289,89 | 3,44k | - |
| 2026-02-11 | Mr. Jonathan C. MeltzerEVP & Chief Operations Officer | 86,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,78k | 3,19% |
| 2026-02-11 | Mr. Jonathan C. MeltzerEVP & Chief Operations Officer | -157,00 | 45,56k | Derivative Exercise and Sale | 289,89 - 290,42 | 2,78k | - |
| 2026-02-11 | Ms. Anita Z. GrahamExec. VP & Chief HR Officer | 247,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,46k | 20,36% |
| 2026-02-11 | Ms. Anita Z. GrahamExec. VP & Chief HR Officer | -109,00 | 31,60k | Derivative Exercise and Sale | 289,89 | 1,46k | - |
| 2026-02-11 | Dr. Brian J. CaveneyEVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | 529,00 | 0,00 | Derivative Exercise and Retained Stock | - | 31,61k | 1,70% |
| 2026-02-11 | Dr. Brian J. CaveneyEVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | -211,00 | 61,17k | Derivative Exercise and Sale | 289,89 | 31,61k | - |
| 2026-02-11 | Ms. Megan D. BaileyExec. VP and President of Central Laboratory Services & International Labcorp | 265,00 | 0,00 | Derivative Exercise and Retained Stock | - | 4,15k | 6,82% |
| 2026-02-11 | Ms. Megan D. BaileyExec. VP and President of Central Laboratory Services & International Labcorp | -138,00 | 40,00k | Derivative Exercise and Sale | 289,89 | 4,15k | - |
| 2026-02-11 | Dr. Paul B. RothmanIndependent Director | 897,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,57k | 53,58% |
| 2026-02-11 | Ms. Kathryn E. WengelIndependent Director | 897,00 | 0,00 | Derivative Exercise and Retained Stock | - | 4,13k | 27,72% |
| 2026-02-11 | Ms. Richelle P. ParhamIndependent Director | 897,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,37k | 36,33% |
| 2026-02-11 | Mr. Peter M. NeupertIndependent Director | 897,00 | 0,00 | Derivative Exercise and Retained Stock | - | 13,78k | 6,96% |
| 2026-02-11 | Dr. Garheng Albert KongVice Chair & Lead Independent Director | 897,00 | 0,00 | Derivative Exercise and Retained Stock | - | 13,74k | 6,98% |
| 2026-02-11 | Ms. Kirsten Marie KliphouseIndependent Director | 897,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,16k | 39,64% |
| 2026-02-11 | Mr. Jeffrey A. DavisIndependent Director | 897,00 | 0,00 | Derivative Exercise and Retained Stock | - | 5,46k | 19,66% |
| 2026-02-11 | Ms. Kerrii B. AndersonIndependent Director | 897,00 | 0,00 | Derivative Exercise and Retained Stock | - | 9,85k | 10,02% |
| 2026-02-10 | Mr. Jonathan C. MeltzerEVP & Chief Operations Officer | -91,00 | 25,19k | Automatic Disposition | 276,79 | 2,70k | -3,27% |
| 2026-02-06 | Ms. Julia A. WangCFO & Exec. VP | 639,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,20k | 113,50% |
| 2026-02-06 | Ms. Julia A. WangCFO & Exec. VP | -254,00 | 70,41k | Derivative Exercise and Sale | 277,20 | 1,20k | - |
| 2026-02-06 | Dr. Brian J. CaveneyEVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | 909,00 | 0,00 | Derivative Exercise and Retained Stock | - | 31,08k | 3,01% |
| 2026-02-06 | Dr. Brian J. CaveneyEVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | -389,00 | 107,26k | Derivative Exercise and Sale | 274,01 - 277,20 | 31,08k | - |
| 2026-02-06 | Mr. Akinbolade OyegunwaExec. VP and Chief Information & Technology Officer | 217,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,94k | 5,82% |
| 2026-02-06 | Mr. Akinbolade OyegunwaExec. VP and Chief Information & Technology Officer | -112,00 | 30,88k | Derivative Exercise and Sale | 274,01 - 277,20 | 3,94k | - |
| 2026-02-06 | Mr. Adam H. SchechterPresident, CEO & Chairman | 5,04k | 0,00 | Derivative Exercise and Retained Stock | - | 92,62k | 5,76% |
| 2026-02-06 | Mr. Adam H. SchechterPresident, CEO & Chairman | -2,67k | 734,98k | Derivative Exercise and Sale | 274,01 - 277,20 | 92,62k | - |
| 2026-02-06 | Mr. Peter J. WilkinsonSenior VP & CAO | 176,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,03k | 9,50% |
| 2026-02-06 | Mr. Peter J. WilkinsonSenior VP & CAO | -91,00 | 25,08k | Derivative Exercise and Sale | 274,01 - 277,20 | 2,03k | - |
| 2026-02-06 | Mr. Mark S. SchroederInsider | 966,00 | 0,00 | Derivative Exercise and Retained Stock | - | 5,93k | 19,48% |
| 2026-02-06 | Mr. Mark S. SchroederInsider | -458,00 | 126,26k | Derivative Exercise and Sale | 274,01 - 277,20 | 5,93k | - |
| 2026-02-06 | Ms. Sandra D. van der VaartInsider | 546,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,85k | 23,71% |
| 2026-02-06 | Ms. Sandra D. van der VaartInsider | -194,00 | 53,48k | Derivative Exercise and Sale | 274,01 - 277,20 | 2,85k | - |
| 2026-02-06 | Mr. Bryan T. VaughnEVP & President of Diagnostics | 236,00 | 0,00 | Derivative Exercise and Retained Stock | - | 5,38k | 4,59% |
| 2026-02-06 | Mr. Bryan T. VaughnEVP & President of Diagnostics | -122,00 | 33,62k | Derivative Exercise and Sale | 274,01 - 277,20 | 5,38k | - |
| 2026-02-06 | Mr. Jonathan C. MeltzerEVP & Chief Operations Officer | 269,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,79k | 10,68% |
| 2026-02-06 | Mr. Jonathan C. MeltzerEVP & Chief Operations Officer | -261,00 | 71,94k | Derivative Exercise and Sale | 274,01 - 277,20 | 2,79k | - |
| 2026-02-06 | Ms. Kathryn Wright KyleExec. VP, Chief Legal Officer and Corporate Secretary | 236,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,29k | 7,73% |
| 2026-02-06 | Ms. Kathryn Wright KyleExec. VP, Chief Legal Officer and Corporate Secretary | -122,00 | 33,62k | Derivative Exercise and Sale | 274,01 - 277,20 | 3,29k | - |
| 2026-02-06 | Ms. Anita Z. GrahamExec. VP & Chief HR Officer | 463,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,21k | 61,73% |
| 2026-02-06 | Ms. Anita Z. GrahamExec. VP & Chief HR Officer | -231,00 | 63,68k | Derivative Exercise and Sale | 274,01 - 277,20 | 1,21k | - |
| 2026-02-06 | Ms. Amy B. SummyEVP, CMO & Consumer Health Lead | 273,00 | 0,00 | Derivative Exercise and Retained Stock | - | 5,58k | 5,15% |
| 2026-02-06 | Ms. Amy B. SummyEVP, CMO & Consumer Health Lead | -172,00 | 47,42k | Derivative Exercise and Sale | 274,01 - 277,20 | 5,58k | - |
| 2026-02-06 | Ms. Megan D. BaileyExec. VP and President of Central Laboratory Services & International Labcorp | 289,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,88k | 8,04% |
| 2026-02-06 | Ms. Megan D. BaileyExec. VP and President of Central Laboratory Services & International Labcorp | -180,00 | 49,55k | Derivative Exercise and Sale | 274,01 - 277,20 | 3,88k | - |
| 2025-11-11 | Mr. Adam H. SchechterPresident, CEO & Chairman | -5,75k | 1,51M | Automatic Disposition | 262,75 | 87,57k | -6,16% |
| 2025-11-01 | Ms. Megan D. BaileyExec. VP and President of Central Laboratory Services & International Labcorp | 191,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,59k | 5,61% |
| 2025-11-01 | Ms. Megan D. BaileyExec. VP and President of Central Laboratory Services & International Labcorp | -179,00 | 46,15k | Derivative Exercise and Sale | 257,84 | 3,59k | - |
| 2025-11-01 | Mr. Akinbolade OyegunwaExec. VP and Chief Information & Technology Officer | 263,00 | 0,00 | Derivative Exercise and Retained Stock | - | 3,73k | 7,59% |
| 2025-11-01 | Mr. Akinbolade OyegunwaExec. VP and Chief Information & Technology Officer | -107,00 | 27,59k | Derivative Exercise and Sale | 257,84 | 3,73k | - |
| 2025-10-31 | Ms. Richelle P. ParhamIndependent Director | -7,01k | 1,78M | Verkauf | 254,28 | 2,47k | -73,95% |
| 2025-08-13 | Ms. Sandra D. van der VaartInsider | -3,90k | 546,40k | Derivative Exercise and Sale | 131,43 - 271,42 | 2,27k | - |
| 2025-08-11 | Mr. Adam H. SchechterPresident, CEO & Chairman | -5,64k | 1,51M | Automatic Disposition | 266,78 | 93,32k | -5,70% |
| 2025-07-30 | Dr. D. Gary GillilandInsider | -2,00k | 529,90k | Verkauf | 264,95 | 6,66k | -23,11% |
| 2025-07-29 | Mr. Peter J. WilkinsonSenior VP & CAO | -202,00 | 52,73k | Verkauf | 261,01 - 261,04 | 1,85k | -9,83% |
| 2025-07-24 | Ms. Kerrii B. AndersonIndependent Director | -3,50k | 980,00k | Automatic Disposition | 280,00 | 8,95k | -28,10% |
| 2025-07-01 | Ms. Kerrii B. AndersonIndependent Director | -500,00 | 132,50k | Automatic Disposition | 265,00 | 12,45k | -3,86% |
| 2025-06-11 | Ms. Kerrii B. AndersonIndependent Director | -500,00 | 130,00k | Automatic Disposition | 260,00 | 12,95k | -3,72% |
| 2025-06-03 | Dr. Brian J. CaveneyEVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | -2,00k | 494,00k | Verkauf | 247,00 | 30,07k | -6,24% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
